Newron Pharmaceuticals S.p.A. (NWPHF)
| Market Cap | 173.70M |
| Revenue (ttm) | 53.20M |
| Net Income (ttm) | 16.40M |
| Shares Out | n/a |
| EPS (ttm) | 0.80 |
| PE Ratio | 10.59 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Average Volume | n/a |
| Open | 12.00 |
| Previous Close | 11.40 |
| Day's Range | 12.00 - 12.00 |
| 52-Week Range | 9.10 - 12.00 |
| Beta | 0.72 |
| RSI | 37.60 |
| Earnings Date | Sep 16, 2025 |
About Newron Pharmaceuticals
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]
News
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron initiates pivotal Phase III trial for evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS).
Newron Presents 2024 Financial Results and Provides 2025 Outlook
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron presents 2024 financial results and provides 2025 outlook.
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
MILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron to participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 am PDT.
Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea
MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron and Myung In Pharm, South Korea's leading specialist CNS pharma company, announce lic...
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
MILAN & MORRISTOWN, N.J. & TOKYO--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron and EA Pharma sign licence for evenamide in Japan & Asia. Newron to receive up to €117 million from upfront payments,...
Newron presents H1 2024 results and provides business update
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on its business activities.
Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron reports data from its 2024 Investor Day indicating evenamide would be uniquely effective in patients with treatment resistant...
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals to host its 2024 Investor Day on June 25, 2024, in New York City. Live webcast beginning at 9:00 AM EDT.
Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City. New hope emerges for treatment-resistant schizop...
Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron reports new data from pivotal study 008A for chronic schizophrenia patients revealing clinically significant efficacy benefits over time.
Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients.
Data from Newron's study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron presents existing evenamide study 014/015 data and future clinical development outlook for evenamide at 2024 SIRS Congress in Florence, Italy.
Newron Presents 2023 Financial Results and Provides 2024 Outlook
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals announces 2023 year-end financial results and provides 2024 business outlook.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement.
Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron reports exceptional one-year clinical results with evenamide for treatment-resistant schizophrenia (TRS). Conference call today at 9:00 am ET.
Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide
MILAN--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron completes enrollment in potentially pivotal study of evenamide for schizophrenia patients who inadequately respond to atypical antipsychotics.
Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron initiates first potentially pivotal study with evenamide in patients with schizophrenia.
Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients.